JPS59227889A - Cermanium complex compound - Google Patents
Cermanium complex compoundInfo
- Publication number
- JPS59227889A JPS59227889A JP58103212A JP10321283A JPS59227889A JP S59227889 A JPS59227889 A JP S59227889A JP 58103212 A JP58103212 A JP 58103212A JP 10321283 A JP10321283 A JP 10321283A JP S59227889 A JPS59227889 A JP S59227889A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- germanium
- compound
- dithiolat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- DKAXSGWOJGVZGP-UHFFFAOYSA-N 3h-dithiole-3-carboxylic acid Chemical compound OC(=O)C1SSC=C1 DKAXSGWOJGVZGP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 125000005843 halogen group Chemical group 0.000 claims abstract description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- 150000001768 cations Chemical class 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 229910052732 germanium Inorganic materials 0.000 claims description 12
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 6
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 6
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 claims description 4
- 150000002291 germanium compounds Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- -1 dithiocarbamic acid anion Chemical class 0.000 abstract description 16
- IEXRMSFAVATTJX-UHFFFAOYSA-N tetrachlorogermane Chemical compound Cl[Ge](Cl)(Cl)Cl IEXRMSFAVATTJX-UHFFFAOYSA-N 0.000 abstract description 8
- 229910052783 alkali metal Inorganic materials 0.000 abstract description 7
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 239000012990 dithiocarbamate Substances 0.000 abstract description 4
- 230000003327 cancerostatic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000000921 elemental analysis Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- NIAAGQAEVGMHPM-UHFFFAOYSA-N 4-methylbenzene-1,2-dithiol Chemical compound CC1=CC=C(S)C(S)=C1 NIAAGQAEVGMHPM-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CUAOYSYBWRKMRN-UHFFFAOYSA-N [O-]C([S+]1SC=CC1)=O Chemical compound [O-]C([S+]1SC=CC1)=O CUAOYSYBWRKMRN-UHFFFAOYSA-N 0.000 description 1
- GSUVLAOQQLOGOJ-UHFFFAOYSA-N [S].[Ge] Chemical compound [S].[Ge] GSUVLAOQQLOGOJ-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、4価のゲルマニウム陽イオンに2座間位子と
なるジチオ化合物陰イオンが2個もしくは3測量位する
ことにより生成する新規ゲルマニウム−含イオウ化合物
錯体、詳しくは、制癌活性を存し、故に癌の予防、治療
剤として期待される新規ゲルマニウム錯化合物、(Ge
(1,2−ジチオラト)z) 、 (M n )”
(G e (1,2−ジチオラNa、に、Caなどのア
ルカIJ金属陽イオンあるいは四アルキルアンモニウム
イオン等カチオ/であり、Xは塩素原子、臭素原子等/
10ゲン原子を表わす。)に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel germanium-sulfur-containing compound complex produced by adding two or three dithio compound anions serving as bidentate sites to a tetravalent germanium cation, specifically, A novel germanium complex compound (Ge
(1,2-dithiolat)z), (Mn)”
(G e (1,2-dithiola, Na, ni, Ca, etc.) or an alkali IJ metal cation such as a tetraalkylammonium ion, etc., and X is a chlorine atom, a bromine atom, etc.
Represents 10 gen atoms. ).
ここで、1,2−ジチオラトは
π
/ \−
R’OOCS
より成る群より選ばれた配位子であり、1,1−ジチオ
ラトが、
NCS−R’OOCS−R’OOCS−より成る群より
選ばれた配位子である。Here, 1,2-dithiolate is a ligand selected from the group consisting of π / \- R'OOCS-, and 1,1-dithiolate is a ligand selected from the group consisting of is the chosen ligand.
ジチオカルバマドはR,d t cより選ばれた配位子
である。Dithiocarbamado is a ligand selected from R, d t c.
ここでR′は水素原子、メチル、エチル、プロピル、イ
ソプロピル基などのアルキル基、メトキシ、エトキシ、
プロポキシ、インプロポキシ基などのアルキルオキシ基
または塩素原子、臭素原子などのハロゲン基を、R“は
水素原子、メチル、エチル、プロピル、イソプロピル基
などのアルキル基を表わす。Here, R' is a hydrogen atom, an alkyl group such as methyl, ethyl, propyl, isopropyl group, methoxy, ethoxy,
R'' represents an alkyloxy group such as a propoxy or impropoxy group or a halogen group such as a chlorine atom or a bromine atom, and R'' represents a hydrogen atom or an alkyl group such as a methyl, ethyl, propyl or isopropyl group.
また、Rは水素原子、メチル、エチル、プロピル、イソ
プロピル基などのアルキル基、フェニル、トリ/I/、
ハロ))’ :y化フェニル基などのアリール基、ベン
ジル、フェニルエチル、メチルベンジル、ハロゲン化ベ
ンジル基などのアラルキル基を表わす。In addition, R is a hydrogen atom, an alkyl group such as methyl, ethyl, propyl, isopropyl group, phenyl, tri/I/,
Halo))': represents an aryl group such as a y-phenyl group, or an aralkyl group such as benzyl, phenylethyl, methylbenzyl, or a halogenated benzyl group.
従来、制ガン剤として多(の薬物が知られて0るが、い
ずれも一長一短がある。近年、金属を含有する錯体の制
ガン効果が注目を集めてきており、代表的なものとして
、白金錯体がよく知られてきている。しかし、白金錯体
は腎毒性などの副作用をもつことが大きな障害となって
いる。Conventionally, many drugs have been known as anticancer agents, but all of them have advantages and disadvantages.In recent years, the anticancer effects of complexes containing metals have attracted attention, and platinum complexes are a typical example. However, platinum complexes have a major obstacle because they have side effects such as nephrotoxicity.
従来、有機ゲルマニウム化合物が薬理活性の面で著しく
注目されて来ている (例えば、特公昭4G−2,49
8号、特公昭4 B −21,855号、特公昭54
− IE30,319号、特公昭54−160、74
2号および特公昭56−11&015号公報参照。)。Conventionally, organic germanium compounds have attracted considerable attention in terms of pharmacological activity (for example, Japanese Patent Publication No. 4G-2, 49
No. 8, Special Publication No. 4 B-21,855, Special Publication No. 1977
- IE30,319, Special Publication No. 54-160, 74
See No. 2 and Japanese Patent Publication No. 56-11 & 015. ).
しかし、従来公知のものはいずれも、2価のゲルマニウ
ムに炭素が直接結合したいわゆる有機ゲルマニウム化合
物である。However, all conventionally known compounds are so-called organic germanium compounds in which carbon is directly bonded to divalent germanium.
一方、以前より和漢薬として用いられている朝鮮にんじ
ん、さるのこしかけ、にんにく等には大量のゲルマニウ
ムが含有されていることが知られているが、これらの薬
理作用とゲルマニウムとの関係は明らかにされていない
。On the other hand, it is known that Korean carrots, saru no koshikake, garlic, etc. that have been used as Japanese and Chinese medicines contain large amounts of germanium, but the relationship between these pharmacological actions and germanium is not clear. It has not been.
本発明者らは、物理化学的により安定な吠態にある4価
のゲルマニウムが、含い右う化合物と安定な錯体化合物
を生成することができると考えて、鋭意研究を重ねた結
果、ゲルマニウム(IV)−含いおう化合物を多数合成
することに成功した。すなわち、四塩化ゲルマニウムに
水溶液あるいは有機溶媒中でジチオール類やジチオカル
バミン酸類のアルカリ金属塩を加えると容易にジチオラ
トあるいはジチオカルバマト錯体が生成することが見出
された。The present inventors believe that tetravalent germanium, which is in a physicochemically more stable state, can form a stable complex compound with a compound containing germanium, and as a result of extensive research, we found that germanium We succeeded in synthesizing a large number of (IV)-containing sulfur compounds. That is, it has been found that when an alkali metal salt of a dithiol or a dithiocarbamate is added to germanium tetrachloride in an aqueous solution or an organic solvent, a dithiolate or dithiocarbamate complex is easily formed.
例えば、四塩化ゲルマニウムに対し、水溶液中で、1,
2−ジチオラトのアルカリ金属塩をモル比1:2で加え
ると(Ge(1,2−ジチオラト)〕が生成し、結晶を
生じる。同様にモル比1:3で加えると(M n )”
(G e (1,2−ジチオラト)〕0eの式であられ
される化合物が生成する。これより、水溶液中では前者
に比べて水溶性が大きいため、M 品化しにくいが、四
アルキルアンモニウムハロゲン化物を加えると四アルキ
ルアンモニウム塩トなり、結晶の収量が多くなることが
理解される。For example, for germanium tetrachloride, 1,
When an alkali metal salt of 2-dithiolate is added at a molar ratio of 1:2, (Ge(1,2-dithiolate)) is produced, resulting in crystals. Similarly, when added at a molar ratio of 1:3, (M n )"
(G e (1,2-dithiolate)) A compound with the formula 0e is produced. From this, it is more soluble in water than the former in an aqueous solution, so it is difficult to commercialize it as a tetraalkylammonium halide. It is understood that the addition of tetraalkylammonium salt results in a higher yield of crystals.
四塩化ゲルマニウムに対し、1,1−ジチオラトアルカ
リ金属塩をモル比1:2で加えた場合も、1.2−ジチ
オラト塩の場合と同様に(Ge(1,1−ジチオラト)
〕の結晶が生成する。When an alkali metal salt of 1,1-dithiolate is added to germanium tetrachloride at a molar ratio of 1:2, as in the case of 1,2-dithiolate salt, (Ge(1,1-dithiolate)
] crystals are formed.
ジチオカルバミン酸アルカリ金属塩の場合は、2価の陰
イオンであるジチオラト類と異なり、1価の陰イオンと
なるため、四塩化ゲルマニウムに対し1:2のモル比で
反応して(Ge(ジチオカルバマド)C1〕を生成する
。In the case of alkali metal dithiocarbamates, unlike dithiolates, which are divalent anions, they become monovalent anions, so they react with germanium tetrachloride at a molar ratio of 1:2 (Ge (dithiocarbamado)). C1] is generated.
これらの化合物は、4価のゲルマニウムイオンのまわり
に4個もしくは6個のいおう原子が配位した構造をもつ
ため安定であり、その構造は元素分析や赤外により容易
に推定できる。These compounds are stable because they have a structure in which four or six sulfur atoms are coordinated around a tetravalent germanium ion, and the structure can be easily estimated by elemental analysis or infrared analysis.
さらに、これらゲルマニウム(IV)−含いおう化合物
錯体は生理活性を有することが期待され、実際にマウス
のエーリッヒ(Ehrlich)腹水腫瘍に対する生理
活性を検討したところ、極めて強い抗腫瘍効果を有する
ことが明らかになった。Furthermore, these germanium (IV)-sulfur-containing compound complexes are expected to have physiological activity, and when we actually investigated their physiological activity against Ehrlich ascites tumors in mice, it was revealed that they have extremely strong antitumor effects. Became.
以下、実施例により本発明の詳細な説明する。Hereinafter, the present invention will be explained in detail with reference to Examples.
実施例1゜
1.373g(5m mol)を水10m1に溶解さ
せ、撹拌下、四塩化ゲルマニウム0.536 g(2,
5m mol)を加えると直ちに黄色沈殿が生成し、
更に撹拌を続けると茶色になる。結晶をグラ、スフイル
ターを用いて吸引濾取、水洗し、塩化カルシウムのデシ
ケータ−中で一夜減圧乾燥すると目的の化合物が茶色結
晶(0,997g1収率85.7%)として得られた。Example 1 1.373 g (5 mmol) was dissolved in 10 ml of water, and while stirring, 0.536 g (2,
5m mol), a yellow precipitate was immediately formed,
If you continue stirring, it will turn brown. The crystals were collected by suction filtration using a glass filter, washed with water, and dried under reduced pressure in a calcium chloride desiccator overnight to obtain the desired compound as brown crystals (0,997 g, yield 85.7%).
。 .
元素分析: (G e (CJS5)2 ) ・2 H
xOトL テノ計算値 C,14,37%;H,0,8
1%;S、63.95%実測値 C,14,04%;I
(,0,10%;S、63.75%赤外吸収スペクトル
:
Viax (cm−’ ) : 421,465,51
1.1058実施例’l (Ge (E t2.d
t c)2C12)の製造四塩化ゲルマニウム0.53
6g(Z5m mo 1 )を塩化メチレンに溶解し、
さらにE t、d t c N a(ジエチルジチオカ
ルバミン酸ナトリtム)0.856g (5m mo
1)を加えると、溶液は次第に着色する。5時間加熱
還流後、生成した食塩と未反応のE t、d t c
N aの結晶をガラスフィルターで濾去し、さらに結晶
を60m1の塩化メチレンで洗浄し、濾液と洗液を合わ
せて、ロータリーエバポレーターで約20m1に減圧濃
縮する。そこにn−へブタン30m1を加え、析出した
黄色結晶をグラスフィルターで吸引濾取し、80℃で一
夜減圧乾燥すると標記の化合物0.906g(収率8z
4%)を得た。Elemental analysis: (G e (CJS5)2 ) ・2 H
xOtoL Teno calculated value C, 14,37%; H, 0,8
1%; S, 63.95% actual value C, 14,04%; I
(,0,10%; S, 63.75% Infrared absorption spectrum: Viax (cm-'): 421,465,51
1.1058 Example'l (Ge (E t2.d
t c) Production of 2C12) Germanium tetrachloride 0.53
Dissolve 6 g (Z5m mo 1 ) in methylene chloride,
Furthermore, 0.856 g (5 m mo
When 1) is added, the solution gradually becomes colored. After heating under reflux for 5 hours, the generated common salt and unreacted E t, d t c
The Na crystals are filtered off using a glass filter, the crystals are further washed with 60 ml of methylene chloride, and the filtrate and washing liquid are combined and concentrated under reduced pressure using a rotary evaporator to a volume of about 20 ml. 30 ml of n-hebutane was added thereto, and the precipitated yellow crystals were collected by suction filtration using a glass filter and dried under reduced pressure at 80°C overnight to obtain 0.906 g of the title compound (yield 8z).
4%).
元素分析:〔Ge((C2H5)2NC82)2C12
〕としての
計算値; C,27,29%;H,4,59%;N、6
.37%;S、29.14%;C1,16,11%実測
値; C,28,28%;II、4.90%、N、8.
72%;S、27.22%;C117,11%
赤外線吸収スペクトル:
Vw+ax(cm−’ ):570,996,1204
,1279.1531トーレエン−3,4−ジチオール
0.71H4g(5腸■of)を0.2N水酸化ナトリ
ウム水溶液50m1に治産させ、さらにGeC1+0.
538g C,1,5m mol>を加えた。直ちに溶
液は黄色に着色し白色沈殿力1生成した。しばらく撹拌
した後G−4グラスフィルターで吸引濾取し、少量の水
で洗浄した。得られた白色結晶をCa Clz、上−夜
減圧乾燥し、ビス() /l/ x y −3,4yチ
オレート)ゲルマニウム(■)0.6735gを得た。Elemental analysis: [Ge((C2H5)2NC82)2C12
] Calculated values as; C, 27,29%; H, 4,59%; N, 6
.. 37%; S, 29.14%; C1, 16, 11% actual value; C, 28, 28%; II, 4.90%, N, 8.
72%; S, 27.22%; C117, 11% Infrared absorption spectrum: Vw+ax (cm-'): 570,996,1204
, 1279.1531 toreene-3,4-dithiol 0.71H4g (5 intestines of) was dissolved in 50ml of 0.2N sodium hydroxide aqueous solution, and GeC1+0.
538 g C, 1.5 mmol> was added. Immediately, the solution turned yellow and a white precipitation of 1 was generated. After stirring for a while, the mixture was collected by suction filtration using a G-4 glass filter and washed with a small amount of water. The obtained white crystals were dried under reduced pressure over CaClz overnight to obtain 0.6735 g of bis()/l/xy-3,4ythiolate)germanium (■).
元素分析:
計算値 C,44,12%;Fl、3.18%;S、3
3.65%実測値 C,44,69%;H,3,04%
;S、32.76%赤外線吸収スペクトル:
Vlax(cm ):4B1,807,1118.14
80トルエン−3,4−ジチオール1.1720g(7
,51101)を0.2N水酸化ナトリウム水溶液85
m1に溶解させ、撹拌下GeC1,0,536g(2,
5m mo 1)を加えた。直ちに反応液むt黄色に
着色し、同時に少量の白色、結晶が析出した。この結晶
を濾過して除き、濾液に、5mlの水に溶解させた[(
C,l(?)、N〕Br1.6122g(5m mo
l)を加えた。反応液は淡黄色の乳液状となったが、2
〜3分後には橙色の油状物が生成した。上清を除き油状
物を水洗した。40〜50℃で一夜減圧乾燥し、0.4
226gの結晶を得た。Elemental analysis: Calculated value C, 44, 12%; Fl, 3.18%; S, 3
3.65% actual value C, 44,69%; H, 3,04%
;S, 32.76% Infrared absorption spectrum: Vlax (cm): 4B1,807,1118.14
80 toluene-3,4-dithiol 1.1720 g (7
, 51101) in a 0.2N aqueous sodium hydroxide solution 85
GeC1,0,536g (2,
5 mmol 1) was added. The reaction solution immediately turned yellow, and at the same time a small amount of white crystals precipitated. The crystals were filtered off and the filtrate was dissolved in 5 ml of water [(
C, l(?), N] Br1.6122g (5m mo
l) was added. The reaction solution became a pale yellow emulsion, but 2
An orange oil formed after ~3 minutes. The supernatant was removed and the oil was washed with water. Dry under reduced pressure at 40-50℃ overnight,
226 g of crystals were obtained.
元素分析:
計算値C,62,38%;H,8,91%;N、2.7
5%;S、18.85%実測値C、C30,73%;)
1,8.16%;N、2.(31%;S、18.15%
赤外線吸収スペクトル:
Vlax(cs−’ ):624,807,97t!、
1114,1453.29804.5−ジメルカプト−
1,3ジチオール−2−チオンカリウム塩2.0590
g (7,5m mo 1)を水15m1に溶解させ
、撹拌下G e C10,536g(25m mol
)を加えると直ちに黄色沈殿が析出した。撹拌を続ける
と黒味を帯びてきた。しばらく撹拌した後遠沈を行い、
上滑をデカンテーションで除いた。水を加えてかきまぜ
再び遠沈し、上清を除いた。得られた結晶を、CaC1
上−夜減圧乾燥し、こげ茶色の結晶1.2644 gを
得た。Elemental analysis: Calculated value C, 62,38%; H, 8,91%; N, 2.7
5%; S, 18.85% actual value C, C30, 73%;)
1, 8.16%; N, 2. (31%; S, 18.15%
Infrared absorption spectrum: Vlax (cs-'): 624,807,97t! ,
1114,1453.29804.5-dimercapto-
1,3 dithiol-2-thione potassium salt 2.0590
G e C10,536 g (25 m mol) was dissolved in 15 ml of water with stirring.
) was added, a yellow precipitate was immediately deposited. As the stirring continued, the mixture became blackish. After stirring for a while, perform centrifugation.
The upper layer was removed by decantation. Water was added, stirred, and centrifuged again, and the supernatant was removed. The obtained crystals were converted into CaC1
The mixture was dried under reduced pressure overnight to obtain 1.2644 g of dark brown crystals.
元素分析:
計算値 C,14,81%:H,0,00%;S、85
.01%実測値 C,14,38%;l(,0,22%
;S、59.77%、(2,5m mol)を加える
と直ちに黄色沈殿が析出した。しばら(撹拌した後G4
グラスフィルターで吸引濾取し、冷水で結晶を洗浄した
。Elemental analysis: Calculated value C, 14,81%: H, 0,00%; S, 85
.. 01% actual value C, 14, 38%; l(, 0, 22%
; S, 59.77%, (2.5 mmol) was added, and a yellow precipitate was immediately deposited. Shibara (after stirring G4
The crystals were collected by suction filtration through a glass filter, and the crystals were washed with cold water.
Ca C12上−夜減圧乾燥すると黄色結晶0.[10
24gが得られた′。When dried under reduced pressure overnight on Ca C12, yellow crystals with 0. [10
24g was obtained.
元素分析:
計算値C,27,22%;o、o、oo%;N、15.
88%;S、36.33%実測m C,25,63%;
l(,1,16%;N、 14.32%; S、28.
27%(10,0m mol)を溶解させN2バブリ
ングして空気酸化を防ぎながら、これにGeC191,
07g (5,0m m o 1 )を加えると瞬間
的に黄色沈殿を生じた。沈殿を64グラスフイルターで
吸引濾取し、−夜減圧乾燥し、結晶1.47 gを得た
。Elemental analysis: Calculated value C, 27, 22%; o, o, oo%; N, 15.
88%; S, 36.33% actual measurement m C, 25.63%;
l(,1,16%; N, 14.32%; S, 28.
GeC191,
When 0.07 g (5.0 mm o 1 ) was added, a yellow precipitate was instantaneously generated. The precipitate was collected by suction filtration through a 64 glass filter and dried under reduced pressure overnight to obtain 1.47 g of crystals.
元素分析:
計算値C,32,24%;l(,2,25%;N、6.
27%;S、2B、69%実測値C,27,81%;l
(,2,03%;N、5.54%;S、21.84%赤
外線吸収スペクトル:
V璽ax (ell−’ ) : 493,732.1
140.1655.2175実施例& 抗腫瘍活性試験
+1) 供試動物
ICR/CRJ系♀マウスを用い、1群5匹、8週令を
使用した。Elemental analysis: Calculated value C, 32, 24%; l(, 2, 25%; N, 6.
27%; S, 2B, 69% actual value C, 27, 81%; l
(,2,03%; N, 5.54%; S, 21.84% Infrared absorption spectrum: Vax (ell-'): 493,732.1
140.1655.2175 Examples & Antitumor Activity Test +1) Test Animals ICR/CRJ strain female mice, 5 mice per group, 8 weeks old were used.
し) 試験方法(in vitro)上記マウスの腹
腔内にエールリッヒ腹水癌細胞lX10個を移植した日
を第0日とし、延命率を調べた。(b) Test method (in vitro) The survival rate was examined on day 0, which was the day when 10 Ehrlich ascites cancer cells were intraperitoneally transplanted into the mouse.
一方、各種ゲルマニウム化合物とインターフェロン誘起
性の可能性も考慮し、−7日目か表 1゜
1) 投与経路 1p
2) 溶解液は生理食塩水で調製
3) 投与口は癌を接種した日を0日とし、(−7〜−
3,÷1〜+5)は−7日目から一3日目までと+11
日目ら+55日目投与する。On the other hand, taking into account the possibility of various germanium compounds and interferon-induced effects, the administration route was determined to be 7 days after administration.2) The solution was prepared with physiological saline. Let it be day 0, (-7~-
3, ÷ 1~+5) is +11 from the -7th day to the 13th day.
Administer on day +55.
ら−3日目、1日目から5日目にそれぞれ1回づつ、合
計10回にわたってip投与し、対照には生理食塩水を
用いた。The drug was administered ip for a total of 10 times, once on day 3 and once on day 1 to day 5, and physiological saline was used as a control.
結果を表1に示した。The results are shown in Table 1.
以上の結果より明らかな如く本発明のゲルマニウム錯化
合物は抗腫瘍性を示す。As is clear from the above results, the germanium complex compound of the present invention exhibits antitumor properties.
特許出願人 味の素株式会社Patent applicant: Ajinomoto Co., Inc.
Claims (1)
物。 (Ge(1,2−ジチオラト)2]。 (Mn)” (Ge (1,2−ジチオラト)3門(
Ge(1,1−ジチオラト)2〕、および(G e (
R2d t c )2 X2)式中、Mnはカチオンを
、nは1または2を、Rはアルキル、アリールまたはア
ラルキル基を、dtcはジチオカルバミン酸陰イオン、
Xはハロゲンを表わす。 21.2−ジチオラトが、 ( I /\− R’00CS より成る群より選ばれた配位子であり、1,1−ジチオ
ラトが、 より成る群より選ばれた配位子である特許請求の範囲第
1項記載の化合物。式中 R/は水素原子、アルキル基
、アルキルオシ基またはハロゲンをR“はアルキル基を
、それぞれ表わす。 & 下記いずれかの式で示されるゲルマニウム錯化合物
の少なくとも一種を仔効成分として含有する癌の予防、
治療剤。 (Ge(1,2−ジチオラト)2〕。 (M n )” (G e (1,2−ジチオラト>
、 〕ee。 (Ge(1,1−ジチオラト)2 〕、および(Ge
(R2d t c)2X2) 式中、Mnはカチオンを、nは1または2を、Rはアル
キル、アリールまたはアラルキル基を、dtcはジチオ
カルバミン酸陰イオンを、Xはハロゲンを、それぞれ表
わす。[Claims] 1. A germanium compound represented by any of the following formulas. (Ge(1,2-dithiolat)2]. (Mn)” (Ge(1,2-dithiolat)3) (
Ge(1,1-dithiolat)2], and (Ge (
R2d t c )2 X2) where Mn is a cation, n is 1 or 2, R is an alkyl, aryl or aralkyl group, dtc is a dithiocarbamate anion,
X represents halogen. 21.2-dithiolate is a ligand selected from the group consisting of ( I /\- R'00CS and 1,1-dithiolate is a ligand selected from the group consisting of A compound according to Item 1 of the scope.In the formula, R/ represents a hydrogen atom, an alkyl group, an alkyloxy group, or a halogen, and R" represents an alkyl group. & At least one germanium complex compound represented by any of the following formulas. Prevention of cancer contained as a child active ingredient,
therapeutic agent. (Ge (1,2-dithiolat)2]. (M n )” (G e (1,2-dithiolat>
, ]ee. (Ge(1,1-dithiolat)2 ], and (Ge
(R2d t c)2X2) In the formula, Mn represents a cation, n represents 1 or 2, R represents an alkyl, aryl or aralkyl group, dtc represents a dithiocarbamate anion, and X represents a halogen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58103212A JPS59227889A (en) | 1983-06-09 | 1983-06-09 | Cermanium complex compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58103212A JPS59227889A (en) | 1983-06-09 | 1983-06-09 | Cermanium complex compound |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS59227889A true JPS59227889A (en) | 1984-12-21 |
Family
ID=14348194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58103212A Pending JPS59227889A (en) | 1983-06-09 | 1983-06-09 | Cermanium complex compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59227889A (en) |
-
1983
- 1983-06-09 JP JP58103212A patent/JPS59227889A/en active Pending
Non-Patent Citations (2)
Title |
---|
CHEMICAL.ABSTRUCTS=1975 * |
J.CHEM.EDUC=1966 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0318464B1 (en) | Antitumor platinum complexes | |
KR100339866B1 (en) | Improvements in platinum complexes | |
JPH05271265A (en) | Platinum complex and its preparation | |
JPS629115B2 (en) | ||
RU2140422C1 (en) | Triplatinum (ii) complexes, and method of preparing thereof | |
JPS6013795A (en) | Diaminocyclohexane platinium complex | |
Lobana et al. | Heterocyclic-2-thione derivatives of silver (I): Synthesis, spectroscopy and structures of mono-and di-nuclear silver (I) halide complexes | |
DE60022372T2 (en) | HALF SANDWICH RUTHENIUM (II) COMPOUNDS WITH NITROGEN-CONTAINING LIGANDS FOR CANCER THERAPY | |
KR100239787B1 (en) | Trinuclear cationic platinum complexes having antitumour activity and pharmaceutical compositions containing them | |
JP3648452B2 (en) | Anticancer platinum (IV) complex for oral administration | |
EP0163316B1 (en) | Platinum-intercalative complexes for the treatment of cancer | |
JPH0247999B2 (en) | ||
US6011166A (en) | Trinuclear cationic platinum complexes having antitumor activity and pharmaceutial compositions containing them | |
JPS59227889A (en) | Cermanium complex compound | |
Kromer et al. | Synthesis and reactivity of [ReBr2 (NCCH3) 2 (CO) 2]−: A new precursor for bioorganometallic chemistry | |
WO2009150448A1 (en) | Improvements in platinum compounds preparation by use of tetrabutylammounium amminetrichloroplatinate as intermediate | |
KR940010295B1 (en) | New anti-cancerous pt-complex derivatives and process for the preparation thereof | |
CZ396292A3 (en) | Pharmaceutical preparation for treating and prophylaxis of infection | |
JPS60214795A (en) | Novel platinum complex | |
US5116831A (en) | Aminoalkyl-substituted cycloalkylamine platinum (II) complexes | |
JPS62108892A (en) | Novel platinum complex | |
JPS6230792A (en) | Novel platinum complex | |
JPH02286694A (en) | New platinum (ii) complex and malignant tumor remedy | |
JPH0247998B2 (en) | HATSUKINSAKUTAI | |
Sirignano | Synthesis, characterization and cytotoxicity studies of novel organo-metallic compounds |